Drug intelligence / Profile preview

CB-839 + Everolimus

Development stage: Unknown
Lead developer: Calithera Biosciences, Inc
Modality: Small Molecules
Administration: Oral

Overview

The drug referred to as "CBE" in the context of NCT02071862 is a combination of CB-839 and Everolimus. CB-839 is a potent and selective small molecule inhibitor of glutaminase, an enzyme critical for glutamine utilization, which many tumor cells rely on for growth and survival. Everolimus is a small molecule inhibitor of mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and survival. This combination is being investigated for its therapeutic potential in advanced clear cell or papillary renal cell carcinoma.

Targets

GLS1 (Glutaminase 1)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on CB-839 + Everolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB-839 + Everolimus.

Explore the full profile